Results 131 to 140 of about 207,267 (296)

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean, Tracy I. George, David P. Ng   +2 more
wiley   +1 more source

Transient loading of CD34+ hematopoietic progenitor cells with polystyrene nanoparticles

, 2017
Sarah Deville,1,2 Wahyu Wijaya Hadiwikarta,1 Nick Smisdom,1,2 Bart Wathiong,1,3 Marcel Ameloot,2 Inge Nelissen,1 Jef Hooyberghs1,3 1VITO, Flemish Institute for Technological Research, Mol, Belgium; 2Biomedical Research Institute, Hasselt University ...
Deville S, Hooyberghs J, Hadiwikarta WW, Nelissen I, Smisdom N, Wathiong B, Ameloot M   +6 more
core  

Variability in responsiveness to lovastatin of the primitive CD34(+) AML subfraction compared to normal CD34(+) cells

, 2008
In the present study, we questioned whether the cholesterol synthesis inhibitor lovastatin potentiates the cytotoxicity of chemotherapeutic agents in the primitive CD34(+) subpopulation of acute myeloid leukemia (AML) cells. AML mononuclear cells (n = 17)
Sluiter, Wim J., de Vries, Elisabeth G. E.; id_orcid, Edo Vellenga, Susan D. P. W. M. de Jonge-Peeters, Folkert Kuipers, van der Weide, Karen, Wim J. Sluiter, Jonge-Peeters, Susan D. P. W. M., Karen van der Weide, de Vries, Elisabeth G. E., Kuipers, Folkert, Weide, Karen, Kuipers, Folkert; id_orcid, de Jonge-Peeters, Susan D. P. W. M., Elisabeth G. E. de Vries, Vellenga, Edo, Vries, Elisabeth G. E.   +16 more
core   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Tumor size in Cd34^−/− surpasses Cd34^+/+ by day 19, due to hematopoietic loss of CD34.

, 2013
A, Average s.c.-injected tumor masses 19 days post-injection in Cd34+/+ and Cd34−/− animals. (Pooled from three experiments, Cd34+/+ n = 15, Cd34−/− n = 16).
Andrew I. Minchinton (353466), Steven Maltby (353460), Matthew J. Gold (353464), Michael R. Gold (353467), Calvin D. Roskelley (24471), Kelly M. McNagny (24472), Spencer Freeman (353462), Jennifer H. E. Baker (353465)   +7 more
core   +1 more source

DinoFlow: Self‐supervised pretraining in flow cytometry enables accurate detection of common hematopathological disorders

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Flow cytometry is an essential component of routine hematological lab testing. Many computational methods have been proposed for the analysis of flow cytometry data, but most have focused on supervised learning for just one or a few specific disorders.
Brendan O'Fallon, Muir Morrison, Mattia Medina Grespan, Nicholas C. Spies, David P. Ng   +4 more
wiley   +1 more source

The ALDH activity of CD34+CD38– HSC is higher than the CD34– bulk in CD34-negative AML.

, 2013
The aldefluor assay was performed on the bulk of cells (AML-464). Cells were subsequently labeled with anti-CD45 PERCP, anti-CD34 PC7, anti-CD38 APC and anti-CD56 PE. (A) The CD34+CD38– stem cells (A, left panel, orange) were negative for CD56 (A, middle
Lisa A. Min (482349), Gerrit J. Schuurhuis (482346), Monique Terwijn (482350), Nick A. de Jonge (482351), Alexander N. Snel (482353), Sonja Zweegman (482354), Gert J. Ossenkoppele (168366), Floris Wouters (482348), Michael H. Meel (482347), Linda Smit (482355), Angele Kelder (482352)   +10 more
core   +1 more source

Differentially expressed genes between CD34+ and CD34- melanocyte stem cells (McSCs) using RNA-Seq analysis

, 2019
Raw counts for all genes for CD34+ and CD34- McSCs that were generated by HTSeq-count. The file comprises of two separate datasets: (a) with all gene counts and (b) without genes with zero counts for all six samples (3 CD34+ McSC samples and 3 CD34- McSC
Thomas Hornyak (6439409)
core   +1 more source

Challenges and Pitfalls to Diagnosing NUTM1‐Rearranged Neoplasia of the Pancreas by Cytology and Ancillary Studies

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fine‐needle aspiration cytology specimens are frequently utilized for ancillary studies to identify diagnostic and prognostic information. This case highlights diagnostic pitfalls and challenges in diagnosing NUTM1‐rearranged neoplasia on pancreatic cytology.
Terrance J. Lynn
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source